2008
DOI: 10.1677/joe-08-0205
|View full text |Cite
|
Sign up to set email alerts
|

Ptgs2 activation by endotoxin mediates the decrease in Igf1, but not in Igfbp3, gene expression in the liver

Abstract: The aim of this work was to analyse the role of cyclooxygenase-2 (Ptgs2) in endotoxin-induced decrease in Igf1 and Igf binding protein-3 (Igfbp3). For this purpose, male Wistar rats were injected with lipolysaccharide (LPS) and/or the Ptgs2 inhibitor meloxicam. LPS induced a significant decrease (P!0 . 01) in serum concentrations of Igf1 and Igfbp3 and their mRNAs in the liver. Meloxicam administration prevented the inhibitory effect of LPS injection on serum Igf1 and its liver mRNA. By contrast, meloxicam adm… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2009
2009
2018
2018

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 54 publications
0
3
0
Order By: Relevance
“…D-Trp(8)-γMSH treatment was able to prevent the effects of LPS on IGF-I levels, whereas it was unable to modify the IGFBP-3 response to LPS injections. The effect of LPS on IGF-I seems to be due, among other mechanisms, to a direct inhibitory action on liver cells [ 43 ], through the induction of COX-2 and iNOS [ 44 , 45 ]. Taking into account that D-Trp(8)-γMSH had an anti-inflammatory effect in the liver, it is not surprising that it prevents the effects of LPS on serum and liver IGF-I levels.…”
Section: Discussionmentioning
confidence: 99%
“…D-Trp(8)-γMSH treatment was able to prevent the effects of LPS on IGF-I levels, whereas it was unable to modify the IGFBP-3 response to LPS injections. The effect of LPS on IGF-I seems to be due, among other mechanisms, to a direct inhibitory action on liver cells [ 43 ], through the induction of COX-2 and iNOS [ 44 , 45 ]. Taking into account that D-Trp(8)-γMSH had an anti-inflammatory effect in the liver, it is not surprising that it prevents the effects of LPS on serum and liver IGF-I levels.…”
Section: Discussionmentioning
confidence: 99%
“…The effects of α MSH treatment on serum levels of IGF-I and IGFBP3 in rats injected with LPS were different, since α MSH was not able to modify the inhibitory effect of LPS on IGF-I, whereas it prevented the LPS-induced decrease in serum IGFBP3 and its expression in the liver. The different responses of both proteins to α MSH treatment may be due to the fact that they are regulated differently [3840]. In addition, they are produced by different liver cells, whereas IGF-I is mainly produced in hepatocytes, IGFBP3 expression is only found in nonparenchymal cells [38, 41].…”
Section: Discussionmentioning
confidence: 99%
“…TNF-α suppresses GH receptor (GHR) expression by reduction of transactivators Sp1/Sp3 binding to a GHR promotor (Denson et al, 2001), IL-6 up-regulates strong inhibitor of GH intracellular signal transduction, SOCS-3 (Wang et al, 2002a;Denson et al, 2003). Other mechanisms of LPS-dependent GH resistance are: decrease in IGF-1 concentration caused by liver cyclooxyganase-2 activation (Briard et al, 2000;Wang et al, 2002b;Martín et al, 2008), direct suppression of GHR expression by MyD88-dependent and -independent TLR4 signaling pathways (Dejkhamron et al, 2007) and promotion of proteolytic GHR cleavage (Wang et al, 2008). Moreover, the ability of GH to promote phosphorylation of signal transducer and activator of transcription (STAT) in the liver is reduced during sepsis (Hong-Brown et al, 2003).…”
Section: Growth Hormonementioning
confidence: 99%